Unternehmensübersicht
Sarepta Therapeutics, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery and development of RNA-targeted therapeutics, including its proprietary siRNA platform and gene therapy modalities, specifically designed to treat rare diseases. The company functions within the Healthcare sector, specifically the Biotechnology industry, where innovation in genetic therapeutic modalities is critical for addressing unmet medical needs for patients with rare conditions. As of the latest reported data, the firm holds a market capitalization of $2.10B and employs approximately 835 individuals across its global operations. The annual revenue recorded over the trailing twelve months amounts to $2.20B, a figure that places the company in a mid-cap range for the biotechnology sector, indicating a substantial but not dominant market position relative to mega-cap pharmaceutical peers. This valuation scale reflects a company that has successfully transitioned from research phases to commercialization, yet the revenue magnitude suggests that while the therapeutic portfolio has achieved market traction, the company still faces the typical scaling challenges inherent in a biotech landscape dominated by larger, more diversified pharmaceutical entities.
Finanzielle Gesundheit
The financial statements reveal a trailing twelve-month revenue of $2.20B, which is offset by a net income of $-713,409,984 and an EBITDA of $-613,251,008, highlighting a significant disparity between top-line sales and bottom-line profitability. The substantial gap between the $2.20B revenue and the negative net income underscores a cost structure where operating expenses, likely driven by high R&D and commercialization costs typical of late-stage biotechs, far exceed current gross margins. Despite the negative earnings, the company maintains a free cash flow of $95.92M, which provides a degree of financial flexibility to fund ongoing operations and development programs without immediate reliance on external capital markets. Profitability metrics show a gross margin of -7.4%, an operating margin of -92.6%, and a profit margin of -32.5%, all of which indicate that the company is currently operating at a loss across all major profitability measures, a common but risky state for firms in the genetic therapy space. Regarding capital structure, the company holds $939.65M in cash against $1.04B in debt, resulting in a debt-to-equity ratio of 91.14, which characterizes the balance sheet as highly leveraged. Although the debt burden is significant, the current ratio stands at 2.32, suggesting that the firm possesses sufficient short-term assets to cover its short-term liabilities, thereby mitigating immediate liquidity risks despite the leverage. Return metrics further illustrate the financial strain, with a return on equity of -53.5% and a return on assets of -11.2%, revealing that management is currently unable to generate positive returns on the capital deployed by shareholders or the asset base.
Bewertungsanalyse
Valuation multiples for Sarepta Therapeutics reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of 7.00, a divergence that implies the market is pricing in a potential future trajectory of earnings where losses may narrow or profitability is anticipated to emerge within the fiscal year. The price-to-book ratio is recorded at 1.84, indicating that the market values the company at a premium of 84% over its tangible book value, a valuation often seen in biotech firms where intangible assets like intellectual property are undervalued on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.95 and an EV/EBITDA of -3.58, suggesting that investors are focusing on revenue generation and potential future cash flows rather than current earnings power or enterprise value efficiency. In terms of trading range, the stock has a 52-week high of $76.67 and a 52-week low of $10.42, placing the current price significantly below the recent highs and reflecting the high volatility and risk premium associated with speculative biotechnology assets. The beta of 0.46 indicates that the stock's price volatility is less than that of the broader market, suggesting a defensive characteristic relative to the high-beta nature of many small-cap biotech stocks, although this lower beta can sometimes mask the underlying binary risk of clinical trial outcomes.
Growth & Income
Growth dynamics are characterized by a revenue growth year-over-year of -32.7%, while earnings growth is listed as N/A due to the lack of positive earnings, indicating that the company is currently contracting rather than expanding its top line. The absence of positive earnings growth means the company is not in a growth phase where revenue expansion translates to profit, and the negative revenue trend implies that the commercialization of existing therapies like EXONDYS 51 may be facing headwinds or market saturation. Regarding income distribution, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not pay dividends and retains all earnings to fund its operations and research activities. This non-dividend strategy aligns with the profile of a growth-oriented biopharmaceutical company that prioritizes reinvestment into its RNA-targeted therapeutic pipeline over shareholder payouts, as paying dividends would be unsustainable given the negative net income. The overall growth and income profile presents a high-risk, zero-income scenario where the primary metric for success is the eventual restoration of profitability rather than current yield or revenue expansion.